These transgenic mice harbor the reverse tetracycline-controlled transactivator (rtTA) and the beta-galactosidase gene (lacZ), and in the presence of tetracycline or a tetracycline analog, expression of lacZ is observed in the nuclei of vascular endothelium in a wide variety of tissues.
James N Topper, Frazier Healthcare Ventures
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Reporter, Inducible, Transactivator) |
Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice harbor co-injected transgenic constructs. The reverse tetracycline-controlled transactivator (rtTA) protein is expressed under the direction of the endothelial-specific receptor tyrosine kinase enhancer/promoter (Tek). The second transgenic construct expresses a nuclear-localizing beta-galactosidase gene (lacZ) under the control of a tetracycline-responsive element (TRE). In the presence of tetracycline or a tetracycline analog (such as doxycycline), selective expression of lacZ is observed in the nuclei of vascular endothelium in a wide variety of tissues (aorta, heart, brain, lung, kidney, liver, spleen, uterus, prostate, stomach, skeletal muscle, large and small intestine). Expression is observed as early as embryonic day 9.5. In the absence of tetracycline, some lacZ expression occurs in the smaller branches of the aorta. Additionally, the donating investigators report a trend towards diminished lacZ expression when the alleles are crossed onto a C57BL/6 background. This strain provides a tool that allows the inducible expression of genes in the vascular endothelium during early developmental stages and in the adult.
This strain is on a genetic background different from that on which the allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
To generate this transgenic line, two transgenic constructs were co-injected into B6CBA fertilized oocytes. The first construct included a 2.1 kb endothelial-specific receptor tyrosine kinase (Tek) promoter fragment, the Tet-on transactivator (tTA), SV40 polyadenylation sequence and a 1.7 kb enhancer sequence derived from Tek intron 1. The other construct consisted of a tetracycline-responsive element, nuclear-localizing beta-galactosidase (lacZ) gene and a SV40 polyadenylation sequence. Although the transgenic constructs are closely linked in this transgenic line (1425), the donating investigators report that no definitive evidence exits indicating that they have cointegrated. The mice were later crossed to Apoe mutant mice (that may have been congenic on the C57BL/6 background). During the development of the colony at The Jackson Laboratory, mice were selected for the (Tek-rtTA,TRE-lacZ) transgene and against the Apoe mutant allele.
Expressed Gene | lacZ, beta-galactosidase, E. coli |
---|---|
Expressed Gene | rtTA, reverse tetracycline-controlled transactivator, E. coli |
Site of Expression | Expresses rtTA in vascular endothelial cells. |
Allele Name | transgene insertion 1425, James N Topper |
---|---|
Allele Type | Transgenic (Reporter, Inducible, Transactivator) |
Allele Synonym(s) | |
Gene Symbol and Name | Tg(Tek-rtTA,TRE-lacZ)1425Tpr, transgene insertion 1425, James N Topper |
Gene Synonym(s) | |
Promoter | tetO, tet operator, |
Promoter | Tek, TEK receptor tyrosine kinase, mouse, laboratory |
Expressed Gene | lacZ, beta-galactosidase, E. coli |
Expressed Gene | rtTA, reverse tetracycline-controlled transactivator, E. coli |
Site of Expression | Expresses rtTA in vascular endothelial cells. |
Strain of Origin | (C57BL/6 x CBA)F1 |
Chromosome | UN |
General Note | Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. In the presence of tetracycline or a tetracycline analog such as doxycycline, selective expression of beta-galactosidase is observed in the nuclei of vascular endothelium in a wide variety of tissues: aorta, heart, brain, lung, kidney, liver, spleen, uterus, prostate, stomach, skeletal muscle, large and small intestine. Expression is observed as early as embryonic day 9.5. In the absence of tetracycline, some beta-galactosidase expression occurs in the smaller branches of the aorta. A trend towards diminished beta-galactosidase expression when the alleles are crossed onto a C57BL/6 background has been reported. |
Molecular Note | Two transgenic constructs were co-injected into B6CBA fertilized oocytes. The first construct included a 2.1 kb endothelial-specific receptor tyrosine kinase (Tek) promoter fragment, the Tet-on transactivator, SV40 polyadenylation sequence and a 1.7 kb enhancer sequence derived from Tek intron 1. The other construct consisted of a tetracycline-responsive element, nuclear-localizing beta-galactosidase gene and a SV40 polyadenylation sequence. Although the transgenic constructs are closely linked in transgenic line 1425, no definitive evidence exits indicating that they have cointegrated. |
Mutations Made By | Peter Teng, Millennium Pharmaceuticals |
When using the Tie2-rTA/TRE-βGal mouse strain in a publication, please cite the originating article(s) and include JAX stock #005493 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or non-carrier for Tg(Tek-rtTA,TRE-lacZ)1425Tpr |
Frozen Mouse Embryo | STOCK Tg(Tek-rtTA TRE-lacZ)1425Tpr/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | STOCK Tg(Tek-rtTA TRE-lacZ)1425Tpr/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | STOCK Tg(Tek-rtTA TRE-lacZ)1425Tpr/J Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | STOCK Tg(Tek-rtTA TRE-lacZ)1425Tpr/J Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.